SGLT2 Inhibitors Prevent Age-Related Kidney Deterioration in Breakthrough Aging Model Study
核心洞察
Researchers demonstrated that SGLT2 (搜索) inhibitors prevented age-related kidney deterioration in African turquoise killifish, revealing specific biological mechanisms behind the drugs' protective effects.
The study established the killifish as a powerful aging model that compresses decades of human-like kidney aging into just four to six months, enabling rapid evaluation of therapeutic interventions.
SGLT2 (搜索)-treated fish retained healthier kidney structure including denser capillary networks, improved filtration barriers, and more stable cellular energy production compared to untreated controls.
A groundbreaking study published in Kidney International reveals that SGLT2 (搜索) inhibitors can prevent age-related kidney deterioration, providing new insights into the biological mechanisms underlying these drugs' protective effects beyond their original diabetes treatment role. The research, conducted by an international team of 13 scientists from MDI Biological Laboratory, Hannover Medical School, and Colby College, utilized the African turquoise killifish as a novel aging model to accelerate kidney research.
Revolutionary Aging Model Accelerates Research
The African turquoise killifish represents one of the fastest-aging vertebrates known, completing its entire lifespan in just four to six months. This unique characteristic allowed researchers to observe decades' worth of human-like kidney aging within months, dramatically accelerating the evaluation of therapeutic interventions compared to traditional mouse models.
The study demonstrated that killifish kidneys undergo structural and functional changes with age that closely mirror human kidney aging, including loss of tiny blood vessels, breakdown of the kidney's filtration barrier, increased inflammation, and disruptions in cellular energy generation and management—classic hallmarks of kidney aging and disease.
SGLT2 Inhibitors Show Protective Effects
Sodium-glucose cotransporter-2 (SGLT2 (搜索)) inhibitors, widely prescribed to treat diabetes-associated heart disease and chronic kidney disease, demonstrated significant protective effects in the killifish model. "These drugs are already known to protect the heart and kidneys in patients with and without diabetes," said Hermann Haller, M.D., senior author of the study and President of MDI Biological Laboratory. "What has been less clear is how they do so."
The research revealed that killifish treated with SGLT2 (搜索) inhibitors retained healthier kidney structure as they aged, including denser networks of capillaries, improved integrity of the kidney's filtration barrier, and more stable cellular energy production. The treatment also preserved communication between different kidney cell types and reduced age-associated inflammatory signaling at the genetic level.
Mechanisms of Protection Revealed
Age-related loss of capillaries, known as vascular rarefaction, emerged as a central feature of kidney decline in untreated fish. As these vessels disappeared, kidney cells shifted away from efficient, mitochondria-based energy production toward less efficient backup pathways.
In contrast, kidneys from SGLT2 (搜索)-treated fish retained healthier capillary networks and showed gene-expression patterns that more closely resembled those of younger animals. These "youthful transcriptional profiles" were associated with improved energy metabolism and lower inflammatory activity.
"Together, these upstream effects provide a biological explanation for clinical observations that the benefits of SGLT2 (搜索) inhibitors often exceed what would be expected from glucose control alone," Haller explained. "They help explain why these drugs consistently reduce kidney and cardiovascular events across diverse patient populations."
Clinical Implications and Future Research
The study's first author, Anastasia Paulmann, M.D., a former postdoctoral researcher at MDI Bio Lab who also holds a clinical position at Hannover Medical School, established and raised the new killifish colony in the Lab's Kathryn W. Davis Center for Regenerative Biology and Aging.
"Seeing these effects emerge so clearly in a rapid-aging model like our killifish was striking," Paulmann said. "What impressed me most was how a seemingly simple drug influences so many interconnected systems within the kidney—from blood vessels and energy metabolism to inflammation and overall function."
The killifish model provides a fast, practical pipeline for evaluating how existing or experimental therapies affect organ resilience with age, helping to prioritize the most promising candidate drugs before they advance to human trials.
The research team is now planning follow-up studies to investigate whether SGLT2 (搜索) inhibition can help restore kidney tissue after age-related damage has already occurred, and how the timing and duration of treatment influence long-term outcomes. This work will be supported by the renovation and expansion of laboratory facilities at MDI Bio Lab, as part of the institution's MDI Bioscience initiative focused on translating fundamental discoveries into strategies that improve human health.